SCHEMBL1361643

SCHEMBL1361643

COc1c(O)ccc(C=O)c1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.59
CA2 P00918 1/20 0.59
ERN1 O75460 8/20 0.50
TRIM24 O15164 3/20 0.50
TRIM33 Q9UPN9 3/20 0.50
TYR P14679 2/20 0.50
ALDH1A1 P00352 3/20 0.42
TLR2 O60603 1/20 0.42
TLR1 Q15399 1/20 0.42
TLR6 Q9Y2C9 1/20 0.42
HPGD P15428 1/20 0.42
ALDH5A1 P51649 1/20 0.42
ABAT P80404 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MAOA P21397 1/20 0.41
CA12 O43570 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA13 Q8N1Q1 1/20 0.39
AOX1 Q06278 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL327222 0.85 CA1 (0.59) CA1CA2ERN1TRIM24TRIM33
SCHEMBL29459741 0.84 CA1 (0.69) CA1CA2ERN1TRIM24TRIM33
SCHEMBL1003414 0.84 CA1 (0.69) CA1CA2ERN1TRIM24TRIM33
SCHEMBL29818698 0.84 CA1 (0.52) CA1CA2ERN1TRIM24TRIM33
SCHEMBL29459651 0.82 CA1 (0.61) CA1CA2ERN1TRIM24TRIM33
SCHEMBL1005010 0.82 CA1 (0.61) CA1CA2ERN1TRIM24TRIM33
SCHEMBL7190769 0.82 XDH (0.47) CA1CA2ERN1TRIM24TRIM33
SCHEMBL7939012 0.81 CA1 (0.59) CA1CA2ERN1TRIM24TRIM33
SCHEMBL6204194 0.80 CA1 (0.44) CA1CA2ERN1TRIM24TRIM33
SCHEMBL358256 0.79 TYR (0.43) CA1CA2ERN1TRIM24TRIM33

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4716685-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2026-04-01 EP disclosed
US-20260070906-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2026-03-12 US disclosed
WO-2024240726-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2024-11-28 WO disclosed
EP-3715118-B1 ADDITIVE MANUFACTURING OF A CHOCOLATE FOOD PRODUCT CHOCOLADEFABRIKEN LINDT & SPRUENGLI AG (CH) 2023-05-03 EP disclosed
CN-114746069-A Three-step multi-tone hair dyeing method 汉高股份有限及两合公司 2022-07-12 CN disclosed
CN-109678923-B Tripterine (iso) ferulic acid ester derivative and preparation method and application thereof 中国药科大学 2021-04-27 CN disclosed
EP-3715118-A1 ADDITIVE MANUFACTURING OF A CHOCOLATE FOOD PRODUCT Chocoladefabriken Lindt & Sprüngli GmbH (DE) 2020-09-30 EP disclosed
WO-2018149882-A1 BINDER DEPOSITION PRINTING OF CHOCOLATE CHOCOLADEFABRIKEN LINDT & SPRÜNGLI GMBH (DE) 2018-08-23 WO disclosed
US-10035803-B2 Synthesis of copanlisib and its dihydrochloride salt BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-07-31 US disclosed
US-20170327505-A1 SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-11-16 US disclosed
US-20090105332-A1 PROCESSES OF MAKING SESQUITERPENOID TASHIRONIN, ITS ANALOGS AND THEIR USES THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF (US) 2009-04-23 US disclosed
CN-101378879-A Dry ice blasting with chemical additives AIR LIQUIDE (FR) 2009-03-04 CN disclosed
EP-1981686-A2 DRY ICE BLASTING WITH CHEMICAL ADDITIVES L'AIR LIQUIDE, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude (FR) 2008-10-22 EP disclosed
US-20070261436-A1 DRY ICE PRODUCTS AND METHOD OF MAKING SAME SUNDARAM MEENAKSHI 2007-11-15 US disclosed
WO-2007088437-A2 DRY ICE BLASTING WITH CHEMICAL ADDITIVES L'AIR LIQUIDE-SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (US) 2007-08-09 WO disclosed
WO-2007088442-A1 DRY ICE PRODUCTS AND METHOD OF MAKING SAME L'AIR LIQUIDE-SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (US) 2007-08-09 WO disclosed
US-20070178811-A1 DRY ICE BLASTING WITH CHEMICAL ADDITIVES SUNDARAM MEENAKSHI 2007-08-02 US disclosed
WO-2006083417-A2 PROCESSES OF MAKING SESQUITERPENOID TASHIRONIN, ITS ANALOGS AND THEIR USES THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2006-08-10 WO disclosed
WO-2003013264-A1 HYPOALLERGENIC CHOCOLATE SOCIETE DES PRODUITS NESTLE S.A. (CH) 2003-02-20 WO disclosed
US-4814417-A Process for producing a liquid crystalline polyester polymer of a cyclohexanedicarboxylic acid and an aromatic diol with pyridine/thionyl chloride catalyst CHISSO CORPORATION (JP) 1989-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10035803-B2 Synthesis of copanlisib and its dihydrochloride salt COPS2, COPS6, COPS4 CA1 3492/4885CA2 1907/4885ERN1 1341/4885
US-20170327505-A1 SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT COPS2, COPS6, COPS4 CA1 3492/4885CA2 1907/4885ERN1 1341/4885
US-20260070906-A1 IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER TLR1, TLR6, TLR8 CA1 3794/4885CA2 1077/4885ERN1 2137/4885
US-20090105332-A1 PROCESSES OF MAKING SESQUITERPENOID TASHIRONIN, ITS ANALOGS AND THEIR USES OXER1, OXSR1, BRS3 CA1 1059/4885CA2 1277/4885ERN1 1526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.